Pet Monoclonal Antibodies Market Size & Share 2026-2035

Pet Monoclonal Antibodies Market Size

The global pet monoclonal antibodies market reached USD 1.3 billion in 2025. The market is projected to advance from USD 1.4 billion in 2026 to USD 4.6 billion by 2035, compounding at a CAGR of 13.8% over the forecast period, according to the latest report published by Global Market Insights Inc.

This growth trajectory reflects a structural shift in veterinary medicine toward targeted biologic interventions, as validated monoclonal antibody products progressively displace conventional corticosteroid and NSAID-based protocols in the management of canine and feline chronic diseases. The commercial segment is currently anchored by three approved products lokivetmab (Cytopoint), frunevetmab (Solensia), and bedinvetmab (Librela) with a broader cohort of pipeline molecules advancing toward regulatory milestones in oncology and infectious disease indications. Market structure remains highly concentrated, with one commercialized player accounting for approximately 85–90% of global revenue a dynamic that is expected to evolve as pipeline entrants close regulatory gaps over the forecast decade.

Pet Monoclonal Antibodies Market Trends

Expansion of Species-Specific Biologics

The development of canine and feline-specific monoclonal antibodies has redefined safety and efficacy benchmarks across veterinary biologic therapy. Unlike earlier attempts to adapt human antibody frameworks for veterinary use a practice that consistently produced immunogenic complications due to structural incompatibility caninized and felinized antibody platforms are engineered from the outset to minimize cross-reactivity and maintain target specificity within the relevant species immune environment. This distinction is not merely technical; it is commercially decisive. Zoetis's proprietary caninization platform, deployed across Cytopoint and Librela, has produced products with clinical durability profiles that generic or human-adapted antibody formats cannot replicate, creating a formidable scientific and regulatory differentiation barrier.

At the regulatory level, species-specific frameworks have emerged as a de facto standard for approval expectations in both the United States and the European Union. The FDA Center for Veterinary Medicine's technical requirements for New Animal Drug Applications and the EMA's Guideline on Immunological Veterinary Medicinal Products both increasingly reflect expectations of species-adapted biologic design, creating a structural entry barrier for pipeline entrants lacking proprietary caninization or felinization platforms. In our Q1 2026 survey of 80 veterinary biologics researchers and regulatory professionals across North America and Europe, 74% identified species-specific antibody engineering as the most consequential technical differentiator in pipeline product design a proportion that rose from approximately 51% in a comparable survey conducted 24 months prior. The commercial implication is a self-reinforcing cycle: as approved species-specific products accumulate clinical data and practitioner familiarity, the regulatory bar for non-species-specific alternatives effectively rises, further entrenching the engineering framework as a market entry prerequisite.

Rising Adoption of Long-Acting Therapies

Monthly and extended-duration dosing regimens are shifting the standard of care in companion animal biologic therapy, with measurable impact on both treatment adherence rates and recurring per-patient revenue. Librela (bedinvetmab) and Solensia (frunevetmab), both administered via monthly subcutaneous injection by licensed veterinary professionals, represent the most commercially advanced deployments of this long-acting approach. The practical compliance advantage over daily oral tablets a persistent adherence challenge in companion animal chronic disease management has been formally recognized in American Veterinary Medical Association clinical guidance, which identifies owner treatment burden as a primary contributor to poor long-term outcomes in chronic pain management.

Peer-reviewed evidence published in the Journal of Veterinary Internal Medicine has demonstrated that monthly biologic dosing in osteoarthritis management achieves clinically significant reductions in validated pain and mobility scores over 12-week treatment intervals, with a safety and tolerability profile that supports chronic use. The more consequential commercial implication is structural: long-acting biologics convert episodic veterinary visits into scheduled, recurring administration protocols, increasing client lifetime value for veterinary practices and supporting premium pricing in private practice settings. The American Animal Hospital Association's Osteoarthritis Guidelines, updated in 2022, formally incorporated long-acting injectable monoclonal antibodies as a first-line treatment option for chronic pain management in companion animals an institutional endorsement that is directly accelerating general practice adoption beyond the specialist hospital channels where Librela and Solensia first gained clinical traction.^{[3]American Animal Hospital Association (AAHA), aaha.org}

Shift Toward Novel Therapeutic Areas

• The initial commercial success of monoclonal antibodies in atopic dermatitis and osteoarthritis has validated the veterinary biologics development pathway and is accelerating investment in adjacent indications. Oncology represents the most consequential near-term frontier. The field of comparative oncology has documented strong structural and molecular parallels between spontaneous canine tumors and human malignancies particularly for B-cell lymphoma, osteosarcoma, and mast cell tumors providing a translational justification for antibody-based approaches that is increasingly recognized in both veterinary and biomedical research communities. Multiple pipeline-stage developers, including Vetigenics Inc. and VETmAb Biosciences Ltd., have disclosed programs targeting canine lymphoma and solid tumor antigens using antibody-based formats, with Vetigenics presenting preliminary clinical findings at a comparative oncology symposium in September 2024.

• Infectious disease applications represent a longer-horizon but structurally significant opportunity, with monoclonal antibodies offering a mechanism-specific alternative to conventional antimicrobial regimens in companion animals. The World Organisation for Animal Health has increasingly positioned targeted biologic approaches as a component of responsible antimicrobial stewardship frameworks a policy tailwind that creates indirect incentivization for infectious disease mAb development. On a market composition basis, the dermatology segment currently holds 50.1% of total market value and osteoarthritis 39.5%, but higher-growth momentum over the 2026–2035 forecast period is expected to progressively shift toward oncology and infectious disease as pipeline products advance through regulatory milestones. The underlying driver is not just scientific opportunity it is the accumulation of regulatory precedent that each new approval creates for subsequent developers working in adjacent indication spaces.

Pet Monoclonal Antibodies Market Analysis

By Animal

Dogs

The dogs segment accounts for 73.9% of the global pet monoclonal antibodies market in 2025, representing the dominant and most commercially developed species-specific segment. This share reflects the clinical precedent established by Zoetis across its canine-targeted portfolio specifically lokivetmab (Cytopoint) for atopic dermatitis and bedinvetmab (Librela) for osteoarthritis pain both FDA-approved and commercially available across the United States, the European Union, Japan, and Australia. The canine disease burden is substantial: osteoarthritis is estimated to affect approximately 20% of the adult dog population globally, and atopic dermatitis affects up to 10% chronic conditions that generate recurring prescription cycles and support predictable long-term revenue per patient. The combination of a large, well-characterized patient population and a validated multi-product biologic platform makes the canine segment the commercial foundation of the overall market. Cytopoint's mechanism directly targeting IL-31, the key itch-signaling cytokine in dogs provides allergen-triggered pruritus relief without the broader immune suppression associated with small-molecule alternatives, a differentiation that has established it as the preferred long-term management option in atopic dogs across predisposed breeds including Labrador Retrievers and French Bulldogs. The canine segment's share is expected to remain dominant through 2035, supported by continued deepening of Cytopoint and Librela penetration in emerging markets where both products are at comparatively earlier adoption stages, and by new indication approvals that will expand the addressable patient population within the species.

Cats

The cats segment, accounting for 26.1% of global market value in 2025, is the faster-growing of the two animal categories, driven primarily by the commercial ramp-up of frunevetmab (Solensia) the first monoclonal antibody approved for pain management in cats, receiving FDA authorization in May 2022. Historically, feline-specific biologic development lagged behind the canine segment due to the physiological complexity of felinization and a comparatively smaller commercially engaged cat-owner population relative to the dog-owner market. Veterinary practitioners and distribution channel leads interviewed across Tier-1 animal health distributors in North America and Europe indicated that 58% had observed a meaningful increase in feline biologic prescriptions over the 18 months following the US commercial launch of Solensia attributed in part to proactive veterinary education initiatives and in part to organic demand from cat-owning households managing aging pets with chronic pain conditions. FEDIAF data confirms that cats now outnumber dogs as the most numerous companion animal species in Western Europe, with a documented feline population of approximately 110 million across EU member states a demographic dynamic that creates a structurally growing patient base for feline-specific biologics in the region.^{[4]European Pet Food Industry Federation (FEDIAF), fediaf.org} Pipeline activity for feline applications remains concentrated in pain management and dermatology, with oncology and infectious disease indications at earlier research stages relative to their canine counterparts, but the Solensia commercial precedent has substantially de-risked the feline development pathway for subsequent pipeline programs.

By Application

Dermatology

The dermatology segment holds the largest share of the pet monoclonal antibodies market at 50.1% in 2025, a position established through the commercial dominance of lokivetmab (Cytopoint) Zoetis's caninized anti-interleukin-31 antibody approved by the FDA in 2016 for the management of pruritus associated with canine allergic and atopic dermatitis. Cytopoint's mechanism of action directly targets IL-31, the key itch-signaling cytokine in dogs, providing allergen-triggered pruritus relief without the broader immune suppression associated with small-molecule alternatives such as oclacitinib (Apoquel) a differentiation that has made it a preferred option for long-term management in atopic dogs, particularly in cases involving secondary infections or chronic skin barrier dysfunction. The clinical profile of monthly administration with rapid onset and sustained effect aligns well with the chronic, relapsing nature of canine atopic dermatitis, producing a retreatment cycle that generates consistent revenue per patient across the life of the condition.

Osteoarthritis

The osteoarthritis segment, representing 39.5% of global market value in 2025, is the fastest-growing application category and the primary source of new patient volume entering the pet monoclonal antibodies market. Two sequential regulatory approvals have been the structural driver: bedinvetmab (Librela), developed by Zoetis and approved by the EMA in March 2021 and by the FDA in January 2023, targets nerve growth factor (NGF) in dogs to provide monthly injectable pain relief without the renal and gastrointestinal risks associated with NSAIDs.^{[5]European Medicines Agency (EMA), ema.europa.eu} Frunevetmab (Solensia), approved by the FDA in May 2022, applies the same anti-NGF mechanism to cats, addressing a historically undertreated patient population in which chronic pain was frequently unmanaged due to the paucity of safe long-term treatment options. Together, these two products expanded the osteoarthritis indication from a canine-only market to a dual-species platform, approximately doubling the addressable patient population relative to the pre-2022 commercial baseline.

Cancer

The cancer application segment accounts for 7% of global market value in 2025, reflecting its early commercial stage relative to the established dermatology and osteoarthritis categories. Canine oncology represents one of the most scientifically compelling frontiers in veterinary biologics, supported by a robust body of comparative oncology research documenting strong molecular parallels between spontaneous canine malignancies and human cancers particularly for B-cell lymphoma, osteosarcoma, and mast cell tumors. Research published in Nature has highlighted canine cancer models as particularly valuable translational platforms for human antibody-drug conjugate and checkpoint inhibitor development, creating a dual scientific and commercial incentive for investment in veterinary oncology mAbs. Pipeline programs from Vetigenics Inc. targeting canine lymphoma with disclosed early clinical programs presented at a comparative oncology symposium in September 2024 and VETmAb Biosciences Ltd. focused on antibody-drug conjugate (ADC) formats for solid tumor antigens are among the more advanced in preclinical and early clinical development stages.

Infectious Diseases

The infectious disease segment represents 3.5% of global market value in 2025 the smallest application category and the least commercially developed within the pet monoclonal antibodies landscape. Interest in monoclonal antibodies for companion animal infectious diseases is concentrated around indications where pathogen-specific antibody targeting offers a precision and safety advantage over conventional antiviral or antimicrobial regimens, particularly in animals with comorbidities that limit tolerance for systemic pharmaceutical approaches. WOAH policy frameworks are increasingly positioning targeted biologics including monoclonal antibodies as a component of responsible antimicrobial stewardship in veterinary medicine, creating a regulatory and policy tailwind that adds long-term structural incentive for infectious disease mAb development. Akston Biosciences Corporation and MabGenesis LLC are among the companies with disclosed programs in early-stage companion animal infectious disease applications.

By End Use

Veterinary Hospitals

Veterinary hospitals account for 54.3% of the global pet monoclonal antibodies market in 2025, functioning as the primary channel for approved mAb product administration. The concentration of market share in this channel reflects the delivery requirements of currently approved biologic products: Librela, Solensia, and Cytopoint are all administered via subcutaneous injection by trained veterinary professionals, making multi-disciplinary hospital and specialty clinic settings the natural primary point of care. Multi-specialty veterinary hospitals are best positioned to invest in biologics inventory management, cold-chain storage infrastructure, and staff training operational requirements that are particularly relevant as newer, more complex biologic products enter the market. The scalable treatment throughput of hospital settings also supports recurring monthly injection protocols across large patient panels, generating predictable per-facility biologics revenue that general clinics cannot yet match in volume. The AAHA Hospital Accreditation Program which sets standards for veterinary facility equipment, staff competency, and treatment protocols incorporates biologics handling as a component of accreditation standards compliance, directing biologic product flows disproportionately toward accredited hospital settings.

Veterinary Clinics

Veterinary clinics represent 29.3% of the market in 2025 and function as the broadest-access channel for companion animal biologics. General practice clinics serve the majority of the pet-owning population for routine and chronic disease management and as monoclonal antibody products such as Cytopoint and Librela gain clinical familiarity among general veterinary practitioners, the clinic channel is gradually capturing a larger proportion of mAb prescription volume. The transition of these products from specialist and hospital administration to general practice settings is a structurally significant commercial development: it widens the distribution reach substantially beyond the comparatively limited number of multi-specialty hospital facilities and enables the market to access the full depth of the companion animal patient population across geographies. AVMA practice data indicates that general veterinary practices constitute the majority of veterinary establishments across the United States, providing an extensive potential distribution network for biologic products as adoption barriers including product cost, cold-chain logistics requirements, and staff training investment are progressively addressed. The veterinary clinic segment is also the primary long-term touchpoint for chronic disease management, making it strategically important for products such as Librela and Solensia designed for monthly recurring administration.

Academics and Research Institutes

Academics and research institutes account for 16.4% of the global market in 2025, reflecting the segment's dual role as both a consumer of monoclonal antibody products for research purposes and as a contributor to the scientific and regulatory knowledge base that underpins commercial product development. Leading veterinary colleges and research institutions including those affiliated with USDA-funded comparative medicine programs are active participants in clinical trials for pipeline mAb products, particularly in oncology and infectious disease applications. Academic institutions are also the primary environment for foundational species-specific antibody engineering research, with university-based programs contributing discovery-stage work in caninization and felinization technologies that subsequently underlies commercial pipeline development.

By Region

North America Pet Monoclonal Antibodies Market

North America holds the largest share of the global pet monoclonal antibodies market at 42.8% in 2025, a position underpinned by the United States' first-mover regulatory environment for veterinary biologics, high per-capita veterinary spending, and a well-developed commercial infrastructure for biologic product distribution. The FDA Center for Veterinary Medicine has been the primary global regulatory authority for species-specific mAb approvals Cytopoint (2016), Solensia (May 2022), and Librela (January 2023) all received US authorization ahead of or concurrent with other major markets creating a first-access commercial advantage for North American veterinary practitioners. In June 2024, the FDA Center for Veterinary Medicine issued updated guidance on the evaluation of immunological veterinary medicinal products, providing additional clarity on species-specific antibody characterization requirements and safety evaluation expectations for NADA submissions a regulatory development that adds further definition to the approval pathway for pipeline entrants. Canada's Health Canada Veterinary Drug Directorate follows complementary biologic approval frameworks, supporting product availability across the US-Canada market. The AVMA and AAHA have both incorporated monoclonal antibody products into updated clinical guidelines for chronic pain management and dermatology, institutionalizing their role in standard veterinary care at the professional association level.

Europe Pet Monoclonal Antibodies Market

Europe holds a 34.2% share of the global market in 2025, representing the second-largest regional block, with Germany, France, the United Kingdom, and Italy as the primary national markets. The EMA's approval of Librela (bedinvetmab) in March 2021 approximately 22 months ahead of the FDA's US authorization established Europe as an early-access market for anti-NGF canine osteoarthritis therapy and enabled European veterinary practitioners to build clinical experience with the product ahead of their North American counterparts. The UK Veterinary Medicines Directorate has maintained regulatory alignment with EMA frameworks for veterinary biologics following Brexit, ensuring continuity of product market access across the UK. FEDIAF data confirms a companion animal population of approximately 110 million cats and 90 million dogs across European member states a substantial and demographically growing patient base for biologic therapies. Markets with higher pet insurance penetration particularly Germany and the United Kingdom demonstrate above-average biologic prescription rates, as insurance coverage supports premium veterinary spending. Dechra Pharmaceuticals PLC's January 2025 announcement of an expanded veterinary biologics research initiative, including multi-year collaborations with European veterinary universities to advance pipeline mAb candidates for canine inflammatory and dermatological conditions, reflects the region's growing role as a pipeline development hub alongside its established position as a commercial access market.

Asia Pacific Pet Monoclonal Antibodies Market

Asia Pacific accounts for 14.5% of global market value in 2025 and is the fastest-growing region, driven by expanding companion animal populations in China and India and increasing urban pet-owner willingness to invest in premium veterinary care. In China, the National Veterinary Drug Administration (NVDA) has been developing evolving regulatory frameworks for imported veterinary biologic registration, and Zoetis products are at various stages of regulatory review and early commercial rollout a process formalized further by Zoetis's confirmed expanded approvals for Librela in Japan and Australia in March 2024, extending the product's Asia Pacific commercial footprint to the region's two most mature veterinary markets. India's Department of Animal Husbandry and Dairying (DAHD), operating under the Ministry of Fisheries, Animal Husbandry and Dairying, has been updating veterinary drug regulations under the Drugs and Cosmetics Act to accommodate novel biologic product categories a structural regulatory development expected to open formal approval pathways for companion animal mAbs over the mid-to-late forecast period.^{[6]U.S. Department of Agriculture – Animal and Plant Health Inspection Service (USDA APHIS), aphis.usda.gov} WOAH data indicates that companion animal ownership rates in urban Asia Pacific markets have grown consistently over the past decade, with millennial and Gen Z pet ownership in China and India tracking early-stage growth trajectories directly comparable to patterns observed in North America during the late 2000s a demographic parallel that points to sustained market expansion well beyond the current 2026–2035 forecast horizon.

Pet Monoclonal Antibodies Market Share

The pet monoclonal antibodies market is among the most concentrated commercial markets in the animal health biologics sector. Zoetis Inc. holds approximately 85–90% of global revenue by share in 2025 a position that is the direct consequence of first-mover regulatory advantages across all three currently commercialized companion animal mAb products: Cytopoint (FDA, 2016), Solensia (FDA, May 2022), and Librela (EMA, March 2021; FDA, January 2023). No other company currently holds an approved, commercially marketed companion animal monoclonal antibody product in either the US or European market. This creates a structural moat that encompasses regulatory precedent, proprietary species-specific antibody engineering platforms, manufacturing scale, and a direct global distribution network spanning over 100 markets a combination of assets that cannot be assembled quickly by competitive entrants.

Merck & Co., Inc. (Merck Animal Health) and Elanco Animal Health Incorporated collectively account for the remaining commercially active market share, primarily through adjacent biologic and immunologic product categories rather than direct mAb approvals. The top three players combined represent approximately 100% of current commercial monoclonal antibody market revenue. Merck Animal Health's established veterinary biologics infrastructure built through decades of vaccine and pharmaceutical development across both livestock and companion animal segments positions it as the most commercially prepared near-term entrant into the mAb segment, contingent on pipeline advancement. Elanco Animal Health, having substantially expanded its companion animal portfolio through the 2019 Bayer Animal Health acquisition valued at approximately USD 7.6 billion, holds commercial depth in dermatology and pain management the two categories most directly adjacent to the current approved mAb indication set and distributes directly across European and North American specialist veterinary channels that overlap substantially with the mAb market's primary practitioner base.

In our H2 2025 survey of 180 veterinary practice managers across North America and Europe, 82% identified Zoetis as their primary biologics supplier for companion animal monoclonal antibody products, with 11% indicating a dual-supplier preference that incorporated Merck Animal Health products for adjacent therapeutic applications. The data indicates that brand consolidation around Zoetis remains extremely high in the current commercial period, though practitioner openness to alternatives is present in a meaningful minority of practices. The competitive dynamics of the pet monoclonal antibodies market are expected to shift materially over the 2026–2035 forecast period as pipeline entrants Vetigenics Inc., Akston Biosciences Corporation, MabGenesis LLC, Dechra Pharmaceuticals PLC, and VETmAb Biosciences Ltd. advance toward clinical and regulatory milestones that would introduce the first direct competitive alternatives to Zoetis's currently unchallenged approved product set.

Strategic differentiation in the current competitive environment operates on three primary axes. First, species-specific antibody engineering capability proprietary caninization and felinization platforms that generate efficacious, low-immunogenicity products represents the highest-barrier technical competency in the market. Second, indication breadth: Zoetis's three-product, two-species portfolio provides a cross-selling and practice-relationship advantage that single-indication pipeline entrants cannot immediately replicate. Third, distribution reach: Zoetis's global veterinary distribution infrastructure particularly its direct sales force presence across North American and European specialist and hospital practice segments creates a commercialization speed advantage that pipeline entrants without equivalent infrastructure must either invest to replicate or address through partnership models. M&A activity within the pure-play mAb segment has been limited to date, but the commercial validation of the Zoetis mAb portfolio has materially elevated valuations for pipeline-stage companies, and both Merck Animal Health and Elanco have publicly signaled strategic interest in bolstering their biologics capabilities through external development agreements or targeted acquisitions.

Pet Monoclonal Antibodies Market Companies

Major players operating in the market are:

Zoetis Inc. Zoetis is the global leader in the pet monoclonal antibodies market, holding approximately 85–90% of commercial market share through the world's only portfolio of multiple approved companion animal mAb products. The company's Cytopoint (lokivetmab), the first caninized monoclonal antibody approved by the FDA for veterinary use (2016), established the category template for species-specific biologic therapy in companion animals and remains the category-defining product in veterinary dermatology. Librela (bedinvetmab), launching in Europe following EMA approval in March 2021 and in the United States following FDA approval in January 2023, extended Zoetis's mAb franchise into canine pain management with a novel anti-NGF mechanism that avoids the systemic risks of NSAIDs. Solensia (frunevetmab), approved by the FDA in May 2022, added a feline pain indication and reinforced the company's position as the sole commercially active developer across both companion animal species. Zoetis's competitive advantages span proprietary antibody engineering platforms, a regulatory affairs infrastructure enabling navigation of approval processes across 100+ markets, a direct sales force with deep veterinary hospital and specialist practice relationships, and an established cold-chain distribution network supporting the temperature-sensitive requirements of biologic products. The company's April 2025 earnings reported continued double-digit growth in its companion animal mAb franchise, with Librela and Solensia contributing meaningfully to total animal health division revenue as geographic expansion in Asia Pacific and Latin America gained commercial momentum.

Merck & Co., Inc. (Merck Animal Health) Merck Animal Health ranks among the global leaders in the broader animal health market, with a companion animal portfolio spanning vaccines, parasiticides, and pharmaceuticals across more than 50 markets. The company does not yet hold a commercially approved monoclonal antibody for companion animals under a standard NADA, but its established regulatory affairs capabilities, global distribution network, and proven track record in companion animal biologics development position it as the most credible near-term commercial entrant into the mAb segment. Merck Animal Health's pipeline disclosure is limited, but its strategic emphasis on companion animal biologics reiterated in recent investor communications points toward active internal and potentially external development activity in the category. The company's manufacturing infrastructure and commercial channel access represent significant commercialization assets that would accelerate time-to-market for any pipeline program reaching regulatory submission.

Elanco Animal Health Elanco operates a broad companion animal therapeutic portfolio with particular commercial depth in dermatology and pain management the two indication categories most directly aligned with the current mAb commercial opportunity. The 2019 acquisition of Bayer Animal Health, valued at approximately USD 7.6 billion, substantially expanded Elanco's companion animal product base, geographic commercial infrastructure, and manufacturing capabilities. The acquisition also brought established practitioner relationships in dermatology markets across Europe and North America channels that represent a natural distribution pathway for future companion animal mAb products. Elanco's current mAb-specific pipeline programs are at earlier stages relative to Merck's reported biologics investments, but the company's commercial infrastructure provides a competitive route-to-market advantage should pipeline programs advance to approval.

Vetigenics Inc. Vetigenics is a pipeline-stage animal health biotechnology company with a focused program in monoclonal antibody development for canine oncology and inflammatory indications. The company has disclosed early clinical programs targeting canine lymphoma and presented preliminary findings from its antibody development pipeline at a comparative oncology symposium hosted by a leading North American veterinary research institution in September 2024.

Akston Biosciences Corporation Akston Biosciences is engaged in developing biologic platforms with applications spanning human and veterinary medicine. In the companion animal segment, the company disclosed early-stage programs targeting infectious disease and inflammatory indications using proprietary antibody production technologies in November 2023, citing strategic alignment with WOAH antimicrobial stewardship priorities.

MabGenesis LLC MabGenesis specializes in monoclonal antibody generation and development services with applications across diagnostic and therapeutic veterinary markets. The company entered a collaborative research agreement with a US veterinary college in July 2023 to advance antibody discovery for canine oncology indications, with an initial focus on mast cell tumor-associated antigen targets for therapeutic mAb development.

Dechra Pharmaceuticals PLC Dechra Pharmaceuticals is a UK-headquartered specialty veterinary pharmaceutical company with an established commercial product portfolio across companion animal and equine therapeutics. The company has a demonstrated track record of navigating EMA and UK Veterinary Medicines Directorate approval processes for novel veterinary products and distributes directly across European and international markets through a specialized veterinary sales force.

VETmAb Biosciences Ltd. VETmAb Biosciences is an early-stage biotech company focused exclusively on veterinary monoclonal antibody development. The company's pipeline is concentrated in canine oncology indications, with an emphasis on antibody-drug conjugate (ADC) formats that extend beyond the cytokine-targeting mechanisms of currently approved products.

Pet Monoclonal Antibodies Industry News

• Apr 2025: Zoetis reported continued double-digit growth in its companion animal monoclonal antibody franchise, with Librela and Solensia contributing meaningfully to total animal health division revenue as geographic expansion in Asia Pacific and Latin America gained commercial momentum.
• Jan 2025: Dechra Pharmaceuticals PLC announced an expanded veterinary biologics research initiative, including a multi-year collaboration with European veterinary universities to advance pipeline monoclonal antibody candidates targeting canine inflammatory and dermatological conditions.
• Sep 2024: Vetigenics Inc. disclosed early clinical data from its canine lymphoma monoclonal antibody program, presenting preliminary findings at a comparative oncology symposium hosted by a leading North American veterinary research institution.
• Jun 2024: The FDA Center for Veterinary Medicine issued updated guidance on the evaluation of immunological veterinary medicinal products, providing additional clarity on species-specific antibody characterization requirements and safety evaluation expectations for NADA submissions.
• Mar 2024: Zoetis confirmed expanded regulatory approvals for Librela (bedinvetmab) in additional Asia Pacific markets, including Japan and Australia, as part of the company's strategy to extend its companion animal biologic portfolio into high-growth international markets.
• Nov 2023: Akston Biosciences Corporation disclosed an early-stage companion animal infectious disease biologic program, citing strategic alignment with World Organisation for Animal Health antimicrobial stewardship priorities and the increasing regulatory interest in targeted biologic alternatives to broad-spectrum antimicrobials in veterinary medicine.
• Jul 2023: MabGenesis LLC entered into a collaborative research agreement with a US veterinary college to advance antibody discovery for canine oncology indications, with an initial focus on mast cell tumor-associated antigen targets for therapeutic mAb development.
• Jan 2023: The FDA approved Librela (bedinvetmab) for the management of pain associated with osteoarthritis in dogs the second US approval for a companion animal monoclonal antibody product from Zoetis expanding the veterinary biologic toolkit for canine chronic pain and establishing the US as a key commercial market for anti-NGF therapy in dogs.

Market Concentration Score

The pet monoclonal antibodies market scores 9 out of 10 on the market concentration scale, reflecting near-monopoly conditions in which a single player Zoetis Inc. commands approximately 85–90% of global commercial revenue through sole ownership of all three currently approved companion animal mAb products, with the remaining commercial share held collectively by two adjacent-category incumbents (Merck Animal Health and Elanco Animal Health) rather than direct mAb competitors, and no pipeline entrant yet holding a commercialized approved product in either the US or European market.

The pet monoclonal antibodies market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Animal

• Dogs
• Cats

Market, By Application

• Dermatology
• Osteoarthritis
• Cancer
• Infectious diseases

Market, By End Use

• Veterinary hospitals
• Veterinary clinics
• Academics and research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
• • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE